An RNA aptamer that specifically binds pancreatic adenocarcinoma up-regulated factor inhibits migration and growth of pancreatic cancer cells.

Previously, we reported that a novel secretory protein, pancreatic adenocarcinoma up-regulated factor (PAUF), which is highly expressed in pancreatic cancer and mediates the growth and metastasis of pancreatic cancer cells. In this study, we generated and characterized a 2'-fluoropyrimidine modified RNA aptamer (P12FR2) directed against human PAUF. P12FR2 binds specifically to human PAUF with an estimated apparent K(D) of 77nM. P12FR2 aptamer inhibits PAUF-induced migration of PANC-1, human pancreatic cancer cells, in a wound healing assay. Moreover, intraperitoneal injection of P12FR2 decreased tumor growth by about 60% in an in vivo xenograft model with CFPAC-1 pancreatic cancer cells, without causing a loss of weight in the treated mice. Taken together, we propose here that PAUF-specific RNA aptamer, P12FR2, has the potential to be effective in the therapy of human pancreatic cancer.

[1]  E. Gragoudas,et al.  Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.

[2]  Y F Hui,et al.  Gemcitabine: a cytidine analogue active against solid tumors. , 1997, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[3]  T. Yeatman,et al.  Outcomes following resection of pancreatic adenocarcinoma: 20-year experience at a single institution. , 2008, Cancer control : journal of the Moffitt Cancer Center.

[4]  H. Ueno,et al.  Adjuvant treatments for resectable pancreatic cancer , 2008, Journal of hepato-biliary-pancreatic surgery.

[5]  C. Rocha-Lima,et al.  Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. , 2010, World journal of gastroenterology.

[6]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[8]  J. Jeekel,et al.  Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist? , 2005, Langenbeck's Archives of Surgery.

[9]  Sheela M. Waugh,et al.  2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165) , 1998, The Journal of Biological Chemistry.

[10]  H. Iwasaki,et al.  Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. , 1997, Blood.

[11]  G. Bepler,et al.  Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients , 2004, Clinical Cancer Research.

[12]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[13]  S. S. Koh,et al.  PAUF functions in the metastasis of human pancreatic cancer cells and upregulates CXCR4 expression , 2010, Oncogene.

[14]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[15]  Andrew D Ellington,et al.  Aptamer therapeutics advance. , 2006, Current opinion in chemical biology.

[16]  P. Chames,et al.  Therapeutic Antibodies for the Treatment of Pancreatic Cancer , 2010, TheScientificWorldJournal.

[17]  D. Bunka,et al.  Development of aptamer therapeutics. , 2010, Current opinion in pharmacology.

[18]  N. Lemoine,et al.  Novel therapies for pancreatic cancer: setbacks and progress. , 2010, Future oncology.

[19]  M. Blank,et al.  Aptamers as tools for target validation. , 2005, Current opinion in chemical biology.

[20]  F. Ducongé,et al.  Aptamers against extracellular targets for in vivo applications. , 2005, Biochimie.

[21]  N. Janjić,et al.  Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. , 1995, Chemistry & biology.

[22]  P. Philip,et al.  Accomplishments in 2008 in the treatment of metastatic pancreatic cancer. , 2009, Gastrointestinal cancer research : GCR.

[23]  L. Gelbert,et al.  An Increase in the Expression of Ribonucleotide Reductase Large Subunit 1 Is Associated with Gemcitabine Resistance in Non-Small Cell Lung Cancer Cell Lines , 2004, Cancer Research.

[24]  Bauke Ylstra,et al.  In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. , 2005, Cancer research.

[25]  Young Woo Park,et al.  Pancreatic adenocarcinoma upregulated factor promotes metastasis by regulating TLR/CXCR4 activation , 2011, Oncogene.

[26]  I. Nomikos,et al.  Current Surgical Aspects of Palliative Treatment for Unresectable Pancreatic Cancer , 2011, Cancers.

[27]  Amy C Yan,et al.  Aptamers and aptamer targeted delivery , 2009, RNA biology.

[28]  R. Brand,et al.  Chemoprevention strategies for pancreatic cancer , 2010, Nature Reviews Gastroenterology &Hepatology.

[29]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Dongling Yang,et al.  Knockdown of CD146 reduces the migration and proliferation of human endothelial cells , 2006, Cell Research.

[31]  S. S. Koh,et al.  Pancreatic adenocarcinoma up‐regulated factor (PAUF), a novel up‐regulated secretory protein in pancreatic ductal adenocarcinoma , 2009, Cancer science.